R Maki

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
  2. pmc EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases
    Kimberly Moore Dalal
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Sarcoma 2008:859407. 2008
  3. ncbi Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
  4. ncbi Role of chemotherapy in patients with soft tissue sarcomas
    Robert G Maki
    Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Rev Anticancer Ther 4:229-36. 2004
  5. doi Pediatric sarcomas occurring in adults
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    J Surg Oncol 97:360-8. 2008
  6. ncbi Immunity against soft-tissue sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 223, New York, NY 10021 6007, USA
    Curr Oncol Rep 5:282-7. 2003
  7. ncbi Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6007, USA
    Int J Cancer 100:623-6. 2002
  8. ncbi Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10021 6007, USA
    Oncologist 12:999-1006. 2007
  9. ncbi A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Dig Dis Sci 52:1964-72. 2007
  10. ncbi A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Cancer 103:1431-8. 2005

Detail Information

Publications72

  1. ncbi Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
    ..Our goal was to investigate the spectrum of pathologic response and molecular alterations in a group of GIST patients, clinically defined as having imatinib-stable/imatinib-responsive lesions, who underwent surgical resection...
  2. pmc EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases
    Kimberly Moore Dalal
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Sarcoma 2008:859407. 2008
    ..Conclusion. EBV-related SMNs have variable aggressiveness. While chemotherapy may slow disease progression, resection and improving the host immune status provide the best opportunity for primary tumor control...
  3. ncbi Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...
  4. ncbi Role of chemotherapy in patients with soft tissue sarcomas
    Robert G Maki
    Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Rev Anticancer Ther 4:229-36. 2004
    ....
  5. doi Pediatric sarcomas occurring in adults
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    J Surg Oncol 97:360-8. 2008
    ..The management of some of these rare tumors is discussed herein, including osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma...
  6. ncbi Immunity against soft-tissue sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 223, New York, NY 10021 6007, USA
    Curr Oncol Rep 5:282-7. 2003
    ..The data regarding the initial evidence of immune responses against sarcomas are reviewed in the context of current or potential clinical studies...
  7. ncbi Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6007, USA
    Int J Cancer 100:623-6. 2002
    ..Imatinib may be useful for patients with locally advanced DFSP, when other options for local therapy are limited...
  8. ncbi Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10021 6007, USA
    Oncologist 12:999-1006. 2007
    ..Given the low response rate to docetaxel as a single agent, it is likely that there is true clinical synergy of the combination. Disclosure of potential conflicts of interest is found at the end of this article...
  9. ncbi A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Dig Dis Sci 52:1964-72. 2007
    ..Examination of this novel approach using multiple dose levels is 1 approach to further investigate the immunogenicity and clinical utility of HSPPC-96 vaccination in this setting...
  10. ncbi A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Cancer 103:1431-8. 2005
    ..Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas...
  11. ncbi Future directions for immunotherapeutic intervention against sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Curr Opin Oncol 18:363-8. 2006
    ..To discuss advances in immunotherapy as pertaining to systemic therapy for sarcomas...
  12. pmc Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer
    Robert G Maki
    Memorial Sloan Kettering Cancer Center, New York, NY 10065 6007, USA
    J Clin Oncol 28:4985-95. 2010
    ..Greater success with these agents clinically is expected when combining the agents with inhibitors of other cell signaling pathways in which cross-resistance has been observed...
  13. ncbi Soft tissue sarcoma as a model disease to examine cancer immunotherapy
    R G Maki
    Sarcoma Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Curr Opin Oncol 13:270-4. 2001
    ..It is hoped that the intersection of cellular immunology and sarcoma molecular biology will lead to new modalities of therapy for this group of patients with this heterogeneous group of diseases...
  14. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  15. ncbi Sarcoma
    R Maki
    Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Oncologist 6:333-7. 2001
    ..Given the lack of new agents for sarcoma therapy since the development of ifosfamide, these studies give hope that the term "effective systemic therapy for sarcoma" might become a reality...
  16. ncbi Multidisciplinary management of soft-tissue sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6007, USA
    Cancer Invest 20:818-24. 2002
  17. ncbi Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007
    ....
  18. ncbi Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature
    Sonam Prakash
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 27:179-87. 2005
    ..The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies...
  19. pmc Molecular characterization of pediatric gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 14:3204-15. 2008
    ....
  20. pmc Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 47:853-9. 2008
    ..A secondary V600E BRAF mutation could represent an alternative mechanism of imatinib resistance. Kinase inhibitors targeting BRAF may be effective therapeutic options in this molecular GIST subset...
  21. pmc ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
    ..It also represents a novel mechanism of oncogenic transcription factor activation...
  22. pmc Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance
    Tianhua Guo
    Departments of Pathology, Medicine, and Surgery, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    Clin Cancer Res 15:6862-70. 2009
    ..The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KIT(AY502-3ins) exon 9 mutation being the most sensitive...
  23. ncbi Outcome of metastatic GIST in the era before tyrosine kinase inhibitors
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 14:134-42. 2007
    ..Treatment of metastatic GIST with imatinib mesylate results in a 2-year survival of approximately 72%. The outcome of patients with metastatic GIST not treated with tyrosine kinase inhibitors is not well defined...
  24. ncbi Recent advances in therapy for gastrointestinal stromal tumors
    Robert G Maki
    Melanoma Sarcoma Service, Department of Medcine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Curr Oncol Rep 9:165-9. 2007
    ..The pathology of GIST, surgical options for primary and metastatic disease, and findings leading to the use of imatinib and sunitinib for GIST are highlighted in this review...
  25. ncbi Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor
    Ronald P Dematteo
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Curr Probl Surg 40:144-93. 2003
  26. doi Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Invest 27:402-6. 2009
    ..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
  27. pmc The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma
    Fritz C Eilber
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg 240:686-95; discussion 695-7. 2004
    ..To determine if chemotherapy offers a survival benefit to patients with large, high-grade, primary extremity liposarcoma...
  28. ncbi De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy
    Mark W Manoso
    Orthopedic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Orthop Relat Res 438:110-5. 2005
    ..Pulmonary metastatectomy improved survival in selected patients...
  29. ncbi A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Cancer J 11:241-7. 2005
    ..Characteristics at presentation and prognostic factors are reviewed. For patients with unresectable disease, progression-free survival with various chemotherapy regimens is described...
  30. doi Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy
    Ryan C Fields
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:328-36. 2011
    ..We examine clinicopathologic factors associated with disease-free survival (DFS) in patients with primary and recurrent DFSP and evaluate responses to multimodality therapy...
  31. ncbi Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis
    Robert J Canter
    Division of Surgical Oncology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2050-60. 2007
    ..To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity...
  32. pmc KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer, New York, New York 10065, USA
    Cancer Res 69:7175-9. 2009
    ..These data provide a basis for the activity of vascular endothelial growth factor receptor-directed therapy in the treatment of primary and radiation-induced AS...
  33. pmc Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    Ronald P Dematteo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 373:1097-104. 2009
    ..We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour...
  34. ncbi Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
    Cristina R Antonescu
    Department of Pathology, Sloan Kettering Institute, New York, New York, USA
    Clin Cancer Res 11:4182-90. 2005
    ..That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies...
  35. ncbi Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
    ..Although the efficacy of tyrosine kinase inhibitors in metastatic GIST depends on tumor mutation status, there have been conflicting reports on the prognostic importance of KIT mutation in primary GIST...
  36. ncbi Management dilemmas due to a paratracheal follicular dendritic cell tumor
    Louis P Voigt
    Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Thorac Surg 82:1898-900. 2006
    ..This malignant tumor created numerous management dilemmas and therapeutic challenges related to the unstable airway and the need for tracheal stenting to bypass the airway obstruction...
  37. ncbi Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors
    Jeremy Kortmansky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1875-84. 2005
    ..We designed a phase I clinical trial of FU in combination with UCN-01...
  38. pmc Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:8862-7. 2003
    ....
  39. ncbi Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
    David R D'Adamo
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:7135-42. 2005
    ..To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS)...
  40. ncbi Mechanisms of sarcomagenesis
    Igor Matushansky
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 19:427-49, v. 2005
    ..Finally, the ways in which these advances in basic science are translating into and redefining clinical practice are highlighted...
  41. pmc Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
    ..Nearly all tumors have an activating mutation in the KIT or, less often, PDGFRalpha, gene. Therapy with tyrosine kinase inhibitors benefits over 80% of patients with advanced GIST, but most patients eventually develop drug resistance...
  42. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  43. ncbi Altered bone and mineral metabolism in patients receiving imatinib mesylate
    Ellin Berman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 354:2006-13. 2006
    ..We observed that hypophosphatemia developed in some patients with either chronic myelogenous leukemia or gastrointestinal stromal tumors who were receiving imatinib...
  44. ncbi Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia
    Mark E Robson
    Clinical Genetics and Gastrointestinal Oncology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:1250-4. 2004
    ..Preliminary correlations between the site of mutation and the clinical phenotype have been proposed, but the strength of these associations is not defined...
  45. pmc Why do patients with low-grade soft tissue sarcoma die?
    Robert J Canter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 15:3550-60. 2008
    ..The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease...
  46. doi Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec)
    Jessica K Gordon
    Department of Rheumatology, Hospital for Special Surgeryy, New York, NY 10021, USA
    Leuk Res 34:827-9. 2010
    ..We found a high prevalence of CK abnormalities in this group and believe that CKs should be monitored during therapy with imatinib...
  47. pmc Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy
    Alex D Drilon
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 113:3364-71. 2008
    ..To the authors' knowledge, there are limited data examining chemotherapy outcomes as a guide to therapeutic decisions for unresectable disease...
  48. pmc Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
    Veridiana Pires de Camargo
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065 6007, USA
    Cancer 116:2258-65. 2010
    ..In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents...
  49. pmc Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
    ..In conclusion, we showed gene expression profiling to be useful in classification and diagnosis, providing insights into pathogenesis and pointing to potential new therapeutic targets of soft tissue sarcoma...
  50. ncbi Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
    ..Recurrent osteosarcoma is a drug-resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET-743) as a salvage therapy in these patients...
  51. pmc A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas
    Igor Matushansky
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA
    Am J Pathol 172:1069-80. 2008
    ..Our results indicate that a degree of developmental maturity can be quantitatively assigned to solid tumors, supporting the notion that transformation of a solid tumor stem cell can occur at distinct stages of maturation...
  52. doi Other targetable sarcomas
    Veridiana Pires de Camargo
    Sarcoma Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Semin Oncol 36:358-71. 2009
    ..In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma...
  53. ncbi Metastatic colon cancer to the ovaries in a Krukenberg-like pattern
    Tiffany A Traina
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:5255-6. 2005
  54. doi A case of high-risk penile epithelioid hemangioendothelioma
    Alexei Wedmid
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Rev Urol 6:223-7. 2009
    ..CT of the chest, abdomen and pelvis was negative for metastatic disease. At this point the patient was referred to a specialist oncology center for further management...
  55. pmc Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway
    Igor Matushansky
    Department of Medicine, Columbia University, New York, New York 10032, USA
    J Clin Invest 117:3248-57. 2007
    ..Our results provide mechanistic insights regarding the cell of origin of MFH, establish what we believe is a novel tumor suppressor role for Wnt signaling, and identify a potential therapeutic differentiation strategy for sarcomas...
  56. pmc IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting
    Mihai Hajdu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pathol 221:300-7. 2010
    ..Our results confirm LOI in several tumours expressing high levels of IGF2, which may explain the observed paraneoplastic hypoglycaemia...
  57. pmc A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients
    Robert J Canter
    Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Clin Cancer Res 14:8191-7. 2008
    ..To identify prognostic factors related to outcome in 255 patients with synovial sarcoma and to construct a preoperative nomogram to predict the risk of disease-specific death...
  58. ncbi The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
    Eva Hernando
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Med 13:748-53. 2007
    ....
  59. ncbi A context dependent role for Wnt signaling in tumorigenesis and stem cells
    Igor Matushansky
    Department of Medicine, Columbia University, New York, New York, USA
    Cell Cycle 7:720-4. 2008
    ..In this review, we will highlight the diverse effect of Wnt signaling on three types of tissue stem cells and their corresponding malignancies...
  60. ncbi Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes
    Janice N Cormier
    Sarcoma Center and Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 22:4567-74. 2004
    ..The role of chemotherapy for these patients remains controversial despite several randomized trials and a meta-analysis...
  61. ncbi Opportunities for improving the therapeutic ratio for patients with sarcoma
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Lancet Oncol 8:513-24. 2007
    ..Research in stem-cell biology and nanotechnology holds promise for additional novel treatment options in the future...
  62. pmc Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma
    Fritz C Eilber
    Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    Ann Surg 246:105-13. 2007
    ..To determine if ifosfamide-based chemotherapy (IF) offers a survival benefit to adult patients with primary extremity synovial sarcoma...
  63. ncbi NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  64. ncbi CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply
    Jay S Wunder
    University Musculoskeletal Oncology Unit and Program in Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Lancet Oncol 8:668-9. 2007
  65. ncbi Evidence-based recommendations for local therapy for soft tissue sarcomas
    Peter W T Pisters
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 25:1003-8. 2007
    ..As such, a complete accounting of potential risks and benefits is appropriate when discussing adjuvant chemotherapy with patients who have stage III disease...
  66. ncbi The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects
    Marco Seandel
    Clin Cancer Res 12:6203-4. 2006
  67. doi Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
    J Clin Oncol 26:626-32. 2008
    ....
  68. ncbi Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
    Thomas A Puchalski
    Dana Farber Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Chemother Pharmacol 50:309-19. 2002
    ....
  69. ncbi Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings
    Rodrigo O B Maegawa
    Leuk Lymphoma 48:2071-4. 2007
  70. doi A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
    Tejas V Patel
    J Natl Cancer Inst 100:282-4. 2008
  71. ncbi Bluish papule in a middle-aged man
    Rachel P Dubroff
    Columbia University Medical Center and Memorial Sloan Kettering Cancer Center, New York, NY
    Arch Dermatol 141:1595-600. 2005